Introduction
Lower-limb peripheral arterial disease (PAD) frequently involves the common femoral artery (CFA) 1, 2 . An estimated 2162 CFA endarterectomies (CFEs) were performed in England in 2011-2012 (data from Hospital Episode Statistics, codes L60⋅1 and L60⋅2). In a review of 1843 CFEs registered in the US National Surgical Quality Improvement Program database from 2005 to 2010, CFEs were found to have an overall risk of combined mortality and morbidity of 15 per cent within 30 days of surgery, with more than 60 per cent of these events occurring after hospital discharge 3 .
Endovascular intervention (angioplasty with or without stenting) is well established as a minimally invasive intervention for PAD, but has not been adopted widely for treatment of the CFA. This is due to: an absence of robust, unbiased evidence on its clinical efficacy, safety and cost profile when applied to CFA segment; no consensus on how this technique should be performed, especially on stenting its branches, which may be diseased at the same time; concern that stent placement in the CFA may limit access options for subsequent treatments; and concern over stent fracture with subsequent arterial occlusion.
More than 50 per cent of patients with PAD undergoing CFE require concomitant endovascular intervention (hybrid procedures) to diseased ipsilateral arteries. Two reviews 4, 5 previously concluded that endovascular interventions to CFA can be performed safely with a high rate of technical success. Since then, two RCTs 6, 7 and two case series 8 -10 on endovascular CFA treatment have been published. This systematic review aimed to assess the safety and efficacy of both endovascular CFA treatment and CFE.
Methods
An a priori protocol was developed for this systematic review according to the PRISMA Statement 11 (Appendix S1, supporting information).
Eligibility criteria
RCTs, non-randomized comparative studies, case series of more than ten participants, and prospective populationbased registry reports of endovascular intervention or endarterectomy for treating CFA atherosclerotic disease in adults with PAD were eligible for inclusion. There were no restrictions on study settings or length of follow-up. There was no restriction on language or publication status.
Patients who underwent concomitant endovascular procedures to the ipsilateral inflow and/or outflow atherosclerotic disease (hybrid procedures) were included. Patients treated for graft stenosis (type IV lesion in the Azéma classification 12 ), thromboangiitis, arteritis or trauma were excluded. Those who underwent concomitant bypass surgery or major amputation were excluded as these are major procedures that may affect results of outcomes.
The studied interventions were endovascular CFA treatment including angioplasty or stenting, and CFE. Outcomes of atherectomy angioplasty and cutting balloon angioplasty may be significantly different from traditional balloon angioplasty and stenting; therefore, studies in which more than 5 per cent of patients underwent atherectomy or cutting balloon angioplasty were excluded.
For comparative studies, the comparators were endovascular CFA intervention versus endarterectomy.
Outcomes were all prespecified and predefined (Table  S1 , supporting information). Safety outcomes included all-cause mortality, perioperative myocardial infarction, wound complications including infection, haematoma, lymph leak and dehiscence, other CFA percutaneous puncture-related complications, stent fracture or deformity, and the need for further operation or procedure for adverse events. Other outcomes included procedure time and duration of hospital stay. Efficacy outcomes included technical success, conversion of endovascular intervention to surgery, symptom improvement, primary CFA patency, need for further revascularization and amputation (major and minor). 
Information sources and search

Study selection and data collection
Two reviewers independently screened the titles and abstracts identified by the literature search, screened full-text copies of all relevant reports for inclusion, and performed data extraction and quality assessment of included studies. Any disagreements were resolved by consensus or arbitration by another author. For studies published in more than one report, the most recent one was used for data collection. A six-section data collection form was developed and piloted in three included studies. No investigators were contacted for additional data.
Risk of bias in individual studies
One checklist was used to assess methodological quality of included RCTs and another for case series and registry (Appendices S2 and S3, supporting information). The checklist was developed by the Review Body for Interventional Procedures (Health Services Research Units at the universities of Aberdeen and Sheffield), an independent review body that carries out systematic reviews for the Interventional Procedures Programme of the UK National Institute for Health and Care Excellence (NICE). The checklists were adapted from several sources 13 -15 and assess risk of bias at the study level. Risk of bias of two conference abstracts was not assessed due to limited information on methodological quality. Information on risk of bias was not incorporated into any data synthesis, but the results were summarized in tables and the impact on data interpretation was discussed descriptively.
Summary measures and synthesis of results
One patient may have both CFAs treated at the same time or at different times, or have one CFA treated more than once; therefore, the number of procedures reported in a study may be greater than the number of patients. For systemic outcomes, for example mortality, the number of patients studied and the incidence rates were recorded for each intervention. For limb-related outcomes, for example primary CFA patency, the number of procedures studied and the incidence rates were recorded for each intervention. When not reported, the denominator was of patients or limbs; assumptions were given as listed above.
For each outcome of each intervention, median incidence rate and range by study design (RCT, registry and case series) were summarized. For outcomes that were reported by three or more studies in each intervention, meta-analysis of proportions was performed including case series, registry and the relevant arm in the RCTs. MedCalc ® software (MedCalc, Ostend, Belgium) was used to calculate the weighted summary proportion under a random-effects model 16, 17 .
Where data were available, short-term (1 year or less) and longer-term (more than 1 year) outcomes were recorded. Within each category, the longest follow-up point was used.
Results
Study characteristics
Some 3877 potential studies were identified, of which 3814 did not meet the inclusion criteria (Fig. 1) . Sixty-three reports were retrieved for full evaluation, of which 31 (from 35 reports) from 12 countries published between 1994 and 2017 were included. Two 6, 7 were RCTs comparing endovascular CFA stenting and CFE, one 3, 18 was a national registry of CFE, and 28 were case series, of which ten 8 -10,19-28 reported endovascular CFA treatment and 18 29 -46 reported CFE. Three studies 8, 33, 44 were published as conference abstracts, and one 31 was published in French. These 31 studies reported a total of 4531 patients (endovascular, 770; endarterectomy, 3761). The two RCTs were not compared directly as they used very different types of stent (bioabsorbable versus metal).
Records identified through database searching n = 3800
Screening
Additional records identified through other sources n = 77
Records screened after duplicates removed n = 3877
Records excluded n = 3814
Full-text articles assessed for eligibility n = 63 Full-text articles excluded n = 28 Case reports or case series with < 10 patients with CFA atherosclerotic disease n = 5 Some patients treated for graft stenosis and results not reported separately n = 4 >5% of patients treated with cutting balloon and results not reported separately n = 1 >5% of patients treated with atherectomy and results not reported separately n = 2 No useful data (studied iliac disease, some patients had concomitant bypass surgery, some patients treated for acute limb ischaemia) n = 12 Not a report of primary research n = 4 Values in parentheses are percentages. *Data from studies that reported corresponding outcome. CFA, common femoral artery; n.a., not applicable.
Patient characteristics
The 12 studies that reported endovascular CFA treatment, including the two RCTs, are shown in Table S2 (supporting information) 6 -10,19-28 , and the 19 studies that reported CFEs, including the national registry study, are shown in Table S3 (supporting information) 3,19,29 -46 . In the endovascular group, for studies that reported data on severity of symptoms, 66⋅5 per cent of procedures were for treatment of claudication and the remainder (33⋅5 per cent) were for critical limb ischaemia ( Table 1) . These proportions were similar to those in the CFE group (claudication 60⋅6 per cent). In the endovascular group, 34⋅7 per cent of procedures were for treatment of CFA occlusion, and the remainder were for CFA stenosis. In the CFE group, data on severity of the CFA lesion were poorly reported; of studies that reported such data, 17⋅8 per cent of procedures were for CFA occlusion ( Table 1 ).
Risk of bias within studies
The highest level of evidence was reported in two RCTs 6, 7 ( Table S4 , supporting information) and a registry 3, 18 (Table  S5 , supporting information). The first RCT 6 randomized 117 patients from 19 centres in France and followed patients for a mean of 2 years for a primary outcome of 30-day morbidity and mortality. It was not clear whether the treatment allocation was adequately concealed. The study was not powered to assess efficacy outcomes. The second RCT 7 randomized 80 patients from a single centre in Japan and followed patients for a mean of 9 months in the endovascular group and 11 months in the endarterectomy group for a primary outcome of wound infection. The treatment allocation was adequately concealed and an intention-to-treat analysis was conducted. The large registry of CFE was based on 5 years of data (2005-2010; 1843 procedures) from the American College of Surgeons National Surgery Quality Improvement Programme 3, 18 . It reported 30-day safety outcomes after CFE including the interval after hospital discharge.
The methodological quality of the 28 case series was generally low ( Table S5 , supporting information). Only ten studies collected data prospectively, of which five 9,10,19 -21,23,27 reported endovascular intervention and five 30, 31, 35, 37, 41 reported CFE. Less than half of the studies (11 of 28) had a sample size of greater than 100 and follow-up of 1 year or more, of which four 9, 10, 19, 22, 27 were in the endovascular group and seven 30,31,34,38 -40,46 were in the CFE group (Table S6 , supporting information).
Technical success
Outcome data from individual studies are shown in Tables S7 and S8 (supporting information).
A total of 81 per cent of studies (25 of 31) reported data on technical success (two RCTs and 23 case series; 2583 procedures) ( Table 2 ). There was no apparent difference in technical success rates between the endovascular group and the endarterectomy group in the two RCTs: 54 of 56 (94 per cent) versus 61 of 61 (100 per cent) respectively for the first RCT 6 Reasons for failure were poorly reported. In the UK study 22 , the reasons reported included residual CFA stenosis greater than 30 per cent, operator unable to cross the diseased segment secondary to dense calcification, procedure abandoned following guidewire causing CFA perforation, and no angiographic improvement following angioplasty. Data on conversion of endovascular intervention to surgery was reported only by the French RCT 6 . Two of the 56 procedures (4 per cent) were converted owing to either technical failure or patient restlessness. Short term, 1 year or less; long term, more than 1 year. *Values in parentheses are ranges. n.a., Not applicable; CFA, common femoral artery.
Safety
There was no reported significant difference in all-cause mortality between the two groups in the two RCTs ( 19 , two access-site pseudoaneurysms 9, 10, 20, 21 , an arteriovenous fistula 20, 21 and closure device-induced CFA stenosis 20, 21 . All required operation, apart from one access-site pseudoaneurysm (Table S8 , supporting information).
Wound infection, lymph leak and dehiscence were a more prominent issue after CFE. The cumulative rate of wound infection was 5⋅9 (95 per cent c.i. 3⋅4 to 9⋅0) per cent (9 studies 3, 6, 19, 29, 32, 37, 38, 42, 45, 46 , 3035 procedures), and that for lymph leak was 5⋅7 (3⋅3 to 8⋅6) per cent (11 studies 6, 30, 31, 34, 37, 38, 40, 41, 43, 45, 46 , 1567 procedures); 0⋅8 per cent of procedures (15 of 1843) involved delayed wound healing or wound dehiscence (registry study 3, 18 ) ( Table 3) . Two CFA stent fractures and one CFA stent deformity were reported in three studies 6, 27, 28 . One fracture of a balloon-expandable stent (WaveMax™; Jomed, Helsingborg, Sweden) was detected 10 months after intervention and required surgical revision 28 . The other stent fracture was detected at 24 months after intervention during a planned radiographic follow-up 6 . The stent (type, name and manufacturer not reported) was placed for a CFA bifurcation lesion. The fracture did not cause any arterial stenosis, and was therefore managed conservatively. Deformity was detected in one patient undergoing an endovascular intervention using a balloon-expandable stent (Express™ LD; Boston Scientific, Natick, Massachusetts, USA) and was also managed conservatively 27 . No description of the deformity was reported, or how and when it was detected.
The registry 3, 18 and 19 case series reported data on the need for further operation for adverse events. The registry reported as many as 10⋅2 per cent of procedures (188 of 1843) requiring return to theatre ( Table 3 ). The cumulative rates were similar for endovascular and CFE procedures: 3⋅1 (95 per cent c.i. 1⋅7 to 4⋅8) per cent (6 studies 9, 19, 20, 22, 23, 28 ; 478 procedures) versus 3⋅2 (1⋅2 to 6⋅3) per cent (14 studies 3,19,29 -32,34,35,38-43,46 ; 3504 procedures) respectively. Reasons for further intervention after endovascular CFA treatment included CFA dissection 19 , access-site pseudoaneurysm, thrombotic occlusion, closure device-related stenosis 20, 21 , intervention-induced distal embolization to crural vessels 22 , arterial thrombosis 9,10 and stent fracture 28 . All reoperations occurred within 30 days of the intervention, apart from treatment of the stent fracture, which occurred 10 months later. In the case of the open CFA endarterectomy, the indications for intervention included haematoma evacuation, wound abscess incision and drainage, wound debridement, lymph leak and haematoma, wound revision, thrombolysis of CFA thrombosis, CFA pseudoaneurysm repair and profunda femoris artery endarterectomy in a case of CFE-site thrombosis.
Efficacy
One RCT 7 and nine case series 19, 23, 24, 26, 29, 36, 37, 41, 45 reported 1-year symptom improvement (subjective success). In the RCT 7 there was no difference between the groups: 70 per cent (28 of 40) in the endovascular group versus 75 per cent (30 of 40) in the CFE group (P = 0⋅40) ( Table 2 ). The cumulative event rate was lower in the endovascular group than that in the CFE group: 75⋅7 (95 per cent c.i. 64⋅6 to 85⋅2) per cent (5 studies 7, 19, 23, 24, 26 ; 224 procedures) versus 90⋅0 (82⋅9 to 95⋅1) per cent (6 studies 7, 29, 36, 37, 41, 45 ; 369 procedures) (Fig. S2, supporting  information) . Only two case series 19, 34 , one in each intervention group and both consisting of 104 procedures, reported symptom improvement for longer than 1 year.
One RCT 7 and 20 case series 8,9,20,23,24,27 -33,35-37,39,41-43,45 reported data on primary CFA patency (objective success). In the RCT 7 , 30-day primary patency after endovascular intervention was 93 per cent (37 of 40) and 100 per cent (40 of 40) after CFE (P = 0⋅241). The difference was more apparent at 1 year after the intervention: 80⋅0 per cent (32 of 40) versus 100 per cent (40 of 40) (P = 0⋅005). Combining across all studies, the endovascular group had a lower 1-year primary patency rate than the CFE group: 78⋅8 (95 per cent c.i. 73⋅3 to 83⋅8) per cent (8 studies 7 -9,20,23,24,27,28 ; 496 procedures) versus 96⋅0 (92⋅2 to 98⋅6) per cent (9 studies 7, 29, 31, 32, 36, 37, 39, 42, 43 ; 498 procedures) respectively. A similar trend was seen for the longer-term primary patency rate ( Table 2 ). The length of follow-up for the four case series 9, 20, 24, 27 in the endovascular group was 18, 24 and 60 months (two studies), and that for the eight case series 30,33,35 -37,41,43,45 in the CFE group was 17, 24 (three studies), 31, 36, 60 and 84 months ( Table 2) .
Eighteen case series reported data on the need for further revascularization but only three studies 19, 22, 39 specified that further revascularization was for CFA restenosis (target lesion) or for disease in other arteries in the same limb (target extremity). Acknowledging this limitation, overall the endovascular group had a higher risk of needing further revascularization at 1 year (16⋅0 (95 per cent c.i. 6⋅1 to 29⋅4) per cent; 4 studies 20, 23, 24, 26 , 167 procedures) in comparison with the CFE group (5⋅8 (1⋅0 to 14⋅2) per cent; 6 studies 29, 30, 35, 39, 43, 44 , 489 procedures). Results after 1 year were similar ( Table 2 ). Duration of follow-up for the four studies 9, 19, 20, 22 in the endovascular group was 18, 24, 28 and 49 months, and that for the seven case series 31, 32, 34, 35, 37, 38, 42 in the CFE group was 16, 36, 39, 43, 60 (two studies) and 180 months. Unfortunately, revascularization was not reported in the RCTs 6, 7 .
No difference in 1-year amputation rates between interventions was reported in either of the RCTs 6,7 . The cumulative risk across all studies (two RCTs and 20 case series) was similar for endovascular procedures (2⋅7 (95 per cent c.i. 1⋅2 to 4⋅8) per cent; 7 studies 6,7,20,22 -24,26 , 381 procedures) and CFE (1⋅9 (0⋅7 to 3⋅8) per cent; 14 studies 6,7,29,31,32,34,35,37 -39,41,43,45,46 , 1508 procedures).
Duration of surgery and length of hospital stay
The mean duration of surgery for the 56 endovascular CFA procedures in the French RCT 6 was 82 min, and 17 patients (30 per cent) received a concomitant endovascular procedure (Table S9 , supporting information). In three case series that reported operating time for CFE alone, the mean duration was 78 min (121 procedures) 30 , 146 min (1843) 3, 18 and 158 min (488) 46 . In four studies that reported duration of CFE where some of the patients (26-57 per cent) received concomitant procedures, the mean operating time was 147 min (75 procedures) 39 , 180 min (65) 37 , 205 min (225) 46 and 207 min (169) 40 .
The mean duration of hospital stay after endovascular CFA treatment was substantially shorter than that for CFE (3⋅2 versus 6⋅3 days respectively) for the 117 patients reported in the French RCT 6 . One registry 3, 18 and seven case series 29, 30, 37, 40, 41, 45, 46 reported length of hospital stay after CFE: mean duration ranged from 2⋅5 to 11⋅9 days.
Discussion
The majority of evidence is of low quality. There was no standardization of endovascular technique and no data on the suitability for either endovascular or endarterectomy in the population of patients with CFA disease requiring revascularization. There may be significant case selection bias in the majority of reported studies.
Endovascular CFA treatment appears to reduce the risk of wound complications and be associated with a shorter length of hospital stay compared with CFE. However, endovascular intervention has a reduced primary patency rate and is associated with an increase in the need for subsequent revascularization procedures. Longer-term outcomes were difficult to assess given the short-term follow-up of the majority of studies.
One of the reasons hindering the widespread adoption of endovascular intervention of the CFA is concern over stent fracture or deformity. Symptomatic stent fracture and stent deformity appeared to be rare during the limited follow-up of included studies, and related only to the use of balloon-expandable stents.
CFA lesions have been classified into four types 12 : type I lesions extend proximally from the CFA into the external iliac artery; type II lesions are limited to the CFA; type III lesions are the most complex, and involve the CFA and its bifurcation; and type IV lesions represent stenosis of a bypass anastomosis. This systematic review excluded type IV lesions 12,47 -49 . The reported endovascular techniques for treating type I and II lesions were relatively consistent, comprising standard balloon angioplasty with or without stent placement. The techniques for type III lesions were poorly reported, with significant variation in reported techniques. The Excellence in Peripheral Artery Disease (XLPAD) registry 50 , reporting on 31 CFA interventions, found plain balloon angioplasty to be the most common technique (87⋅5 per cent), followed by drug-coated balloon therapy (37⋅5 per cent), atherectomy (37⋅5 per cent), stenting (18⋅8 per cent) and cutting balloon angioplasty (12⋅5 per cent). Combinations of these treatments were also described. At 1-year follow-up, three target vessel revascularizations and one stroke were reported. The range of interventions performed indicates a need for optimization and standardization of the technique for treating type III lesions.
Calcification is a problem for endovascular intervention. As mentioned in the XLPAD registry 50 , some practitioners use atherectomy angioplasty in selected patients to deal with this problem. Atherectomy angioplasty uses a special atheroma debulking device to remove atheromatous plaque. It is, however, a technique that is rarely used in the UK.
The methodological quality of the included studies was low. Only two small RCTs 6,7 were available; both used safety as primary outcome and were underpowered to assess efficacy. The national registry 3, 18 has a large sample size, but reported only 30-day safety outcomes. The methodological quality of the 28 included case series was low in general, with only one-third collecting data prospectively, and less than half having a sample size of more than 100 and follow-up of 1 year or longer.
There also appeared to be case selection bias in some studies; for example, the French RCT 6 included 17 centres and yet took 30 months to recruit 117 patients, of whom 87⋅1 per cent had less severe PAD (claudication). This suggests that there was considerable case selection for enrolment of patients into the study, and does not represent patients that most UK vascular surgeons would consider for treatment with critical limb ischaemia. Future clinical trials should report outcomes of each group of patients separately.
Categorizing wound complications according to severity is important, but few reports did this. This made metaanalysis by severity of wound complications inappropriate owing to the small number of studies for each intervention.
Endovascular intervention is a potential treatment for CFA atherosclerotic disease. There is, however, insufficient evidence to allow a reliable comparison of its effectiveness with that of surgery, or to determine its safety and efficacy profile. None of the included studies reported cost data, and the financial impact of endovascular intervention is unknown.
